Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.9555 -0.2845 (-22.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,222,914
Open 1.000
Bid (Size) 0.9500 (2)
Ask (Size) 0.9901 (3)
Prev. Close 1.240
Today's Range 0.9002 - 1.030
52wk Range 0.7500 - 1.690
Shares Outstanding 36,645,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Gapping stocks in Friday's session
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill

Performance

YTD
-29.7%
-29.7%
1 Month
-26.5%
-26.5%
3 Month
-22.9%
-22.9%
6 Month
-9.0%
-9.0%
1 Year
-19.0%
-19.0%

More News

Read More
What's going on in today's pre-market session
Via Chartmill
Earnings Scheduled For August 14, 2025
Via Benzinga
Earnings Preview For RenovoRx
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
RenovoRx Revenue Jumps 28 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
RenovoRx Inc. (NASDAQ:RNXT) Q2 2025 Earnings: Revenue Surpasses Estimates, Shares Climb on Positive Results
Via Chartmill
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
From RenovoRx, Inc.
Via Business Wire
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
From RenovoRx, Inc.
Via Business Wire
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Earnings Scheduled For May 15, 2025
Via Benzinga
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
From RenovoRx, Inc.
Via Business Wire
These stocks are moving in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire

Frequently Asked Questions

Is RenovoRx, Inc. - Common Stock publicly traded?
Yes, RenovoRx, Inc. - Common Stock is publicly traded.
What exchange does RenovoRx, Inc. - Common Stock trade on?
RenovoRx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for RenovoRx, Inc. - Common Stock?
The ticker symbol for RenovoRx, Inc. - Common Stock is RNXT on the Nasdaq Stock Market
What is the current price of RenovoRx, Inc. - Common Stock?
The current price of RenovoRx, Inc. - Common Stock is 0.9555
When was RenovoRx, Inc. - Common Stock last traded?
The last trade of RenovoRx, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of RenovoRx, Inc. - Common Stock?
The market capitalization of RenovoRx, Inc. - Common Stock is 35.02M
How many shares of RenovoRx, Inc. - Common Stock are outstanding?
RenovoRx, Inc. - Common Stock has 35M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.